Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rudolf M Huber

Showing results (91-100 of 107) with videos related to

Pageof 11
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 25, 2022
Lung Cancer Screening in Persons Who Never Smoked Has to be Evaluated-A Response to Letter to the EditorAnna Kerpel-Fronius, Martin C Tammemägi, Milena Cavic, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 6, 2026
A Game-Changing 20 Years: Progress and Future Directions in Lung Cancer ScreeningStephen Lam, David R Baldwin, Anand Devaraj, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2018
Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical TrialsD Ross Camidge, Dong-Wan Kim, Marcello Tiseo, et al.
The European Respiratory Journal|April 16, 2026
Reply regarding the European Respiratory Society and European Society of Thoracic Surgeons clinical practice guideline on fitness for curative intent treatment of lung cancerAlessandro Brunelli, Georgia Hardavella, Rudolf M Huber, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 23, 2019
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA TrialRudolf M Huber, Karin H Hansen, Luis Paz-Ares Rodríguez, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2025
Safety and Sample Adequacy for Comprehensive Biomarker Testing of Bronchoscopic Biopsies: An American Association of Bronchology and Interventional Pulmonology and International Association for the Study of Lung Cancer Clinical Practice GuidelineUdit Chaddha, Abhinav Agrawal, Uzair Ghori, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 26, 2025
Lung Cancer Screening Program Quality Indicators-Review and Recommendations: An International Association for the Study of Lung Cancer Delphi Process StudyMartin C Tammemägi, Andrea Borondy-Kitts, John K Field, et al.
Lung Cancer (Amsterdam, Netherlands)|September 7, 2016
Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLCAndrea Ardizzoni, Marcello Tiseo, Luca Boni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2017
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II TrialDong-Wan Kim, Marcello Tiseo, Myung-Ju Ahn, et al.
JTO Clinical and Research Reports|September 6, 2022
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory <i>ALK</i>+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) TrialsScott N Gettinger, Rudolf M Huber, Dong-Wan Kim, et al.
Pageof 11

Showing results (91-100 of 107) with videos related to

Sort By:
Pageof 11
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 25, 2022
Lung Cancer Screening in Persons Who Never Smoked Has to be Evaluated-A Response to Letter to the EditorAnna Kerpel-Fronius, Martin C Tammemägi, Milena Cavic, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 6, 2026
A Game-Changing 20 Years: Progress and Future Directions in Lung Cancer ScreeningStephen Lam, David R Baldwin, Anand Devaraj, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2018
Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical TrialsD Ross Camidge, Dong-Wan Kim, Marcello Tiseo, et al.
The European Respiratory Journal|April 16, 2026
Reply regarding the European Respiratory Society and European Society of Thoracic Surgeons clinical practice guideline on fitness for curative intent treatment of lung cancerAlessandro Brunelli, Georgia Hardavella, Rudolf M Huber, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 23, 2019
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA TrialRudolf M Huber, Karin H Hansen, Luis Paz-Ares Rodríguez, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2025
Safety and Sample Adequacy for Comprehensive Biomarker Testing of Bronchoscopic Biopsies: An American Association of Bronchology and Interventional Pulmonology and International Association for the Study of Lung Cancer Clinical Practice GuidelineUdit Chaddha, Abhinav Agrawal, Uzair Ghori, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 26, 2025
Lung Cancer Screening Program Quality Indicators-Review and Recommendations: An International Association for the Study of Lung Cancer Delphi Process StudyMartin C Tammemägi, Andrea Borondy-Kitts, John K Field, et al.
Lung Cancer (Amsterdam, Netherlands)|September 7, 2016
Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLCAndrea Ardizzoni, Marcello Tiseo, Luca Boni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2017
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II TrialDong-Wan Kim, Marcello Tiseo, Myung-Ju Ahn, et al.
JTO Clinical and Research Reports|September 6, 2022
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory <i>ALK</i>+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) TrialsScott N Gettinger, Rudolf M Huber, Dong-Wan Kim, et al.
Pageof 11